Health Investment Returns: Harnessing Health as a Strategic Economic Asset
Health as a Strategic Economic Imperative
A country's enduring strength stems not solely from military or industrial resources but from the vitality and productivity of its populace. A recent EFPIA Guest Blog by Michael Oberreiter frames he...
Emblaveo MDR Infections: Evaluating a New Solution for Multidrug-Resistant Gram-Negative Infections
Emblaveo Approved for MDR Gram-Negative Infections
Emblaveo MDR infections pose a growing threat in Portugal, with the public assessment report evaluating Emblaveo (aztreonam + avibactam) for financing under Decree-Law No. 97/2015....
Promising Advances in TNBC Treatment: Sacituzumab Govitecan in First-Line Therapy
Sacituzumab Govitecan Shows Promise in First-Line TNBC Therapy
Sacituzumab govitecan for TNBC represents a major step forward in treating untreated
Interchangeable Biosimilar Approval: FDA Greenlights Poherdy as First to Perjeta
FDA Grants First Interchangeable Biosimilar Approval for HER2-Positive Breast Cancer Treatment
The U.S. Food and Drug Administration (FDA) has issued an interchangeable biosimilar approva...
HIV Therapy Advancements: Promising Results from Bictegravir/Lenacapavir Combination Trial
Breakthrough Single-Tablet Regimen Drives HIV Therapy Advancements
Gilead Sciences has announced promising topline results from the Phase 3 ARTISTRY-1 trial, demonstrating that an investigational single-tablet regim...
Navigating Targeted Therapy Access: Innovations and Challenges in High-Cost Treatments
Evolving Landscape of Targeted Therapies and Access Challenges
Expanding targeted therapy access remains a critical challenge amid the pharmaceutical market's shift toward high-cost innovations, such as orphan drugs and...
